Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A 12-week, Double-blind, Randomized Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate / Simvastatin 145/20mg and Fenofibrate / Simvastatin 145/40mg Tablets vs. Matching Monotherapies in Dyslipidemic Subjects at High Risk of Cardiovascular Disease.
INTERVENTIONAL
Inicio: 1 de jun de 2012
ID: NCT01674712
Completado
Fase 2
ClinicalTrials.gov
A Phase II Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Cotadutide in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
INTERVENTIONAL
Inicio: 14 de jul de 2022
ID: NCT05364931
Completado
ClinicalTrials.gov
A Multicountry, Multicentre, Non-interventional, Prospective Study to Determine the Prevalence of EGFR Mutations in Patients With Early-stage, Surgically Resected, Non-squamous, Non-small Cell Lung Cancer
OBSERVATIONAL
Inicio: 4 de mar de 2021
ID: NCT04742192
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3540378 in Adults With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
INTERVENTIONAL
Inicio: 3 de feb de 2023
ID: NCT05592275
Completado
Fase 3
ClinicalTrials.gov
Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia
INTERVENTIONAL
Inicio: 17 de dic de 2013
ID: NCT01954394
Por invitación
Fase 3
ClinicalTrials.gov
Long-term Extension Study to Evaluate the Safety and Efficacy of Riliprubart (SAR445088) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
INTERVENTIONAL
Inicio: 1 de abr de 2025
ID: NCT06859099
Completado
Fase 3
ClinicalTrials.gov
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
INTERVENTIONAL
Inicio: 1 de mar de 2012
ID: NCT01516736
Terminado
Fase 3
ClinicalTrials.gov
A 46-week, Double-blind, Placebo-controlled, Phase 3 Study With a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
INTERVENTIONAL
Inicio: 24 de ene de 2018
ID: NCT03420781
Completado
Fase 3
ClinicalTrials.gov
A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inhibition and Patient Outcomes]
INTERVENTIONAL
Inicio: 1 de oct de 2006
ID: NCT00391872
Completado
Fase 2
ClinicalTrials.gov
A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 15 de oct de 2015
ID: NCT02349061
Completado
Fase 1
ClinicalTrials.gov
A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI-545, a Fully Human Anti-Interferon-Alpha Monoclonal Antibody, in Patients With Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 1 de jun de 2007
ID: NCT00482989
Completado
Fase 3
ClinicalTrials.gov
A 52 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 3-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 200/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 200/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) ALONE OR ON TOP OF OPEN-LABEL TIOTROPIUM 2.5 µg RESPIMAT® IN PATIENTS WITH ASTHMA UNCONTROLLED ON HIGH DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2-AGONISTS
INTERVENTIONAL
Inicio: 6 de abr de 2016
ID: NCT02676089
Completado
Fase 4
ClinicalTrials.gov
A Randomized, Double-blind, Parallel-group, 26-week Study Comparing the Efficacy and Safety of Indacaterol (Onbrez® Breezhaler® 150 mcg o.d.) With Salmeterol/Fluticasone Propionate (Seretide® Accuhaler® 50 mcg/500 mcg b.i.d.) in Patients With Moderate Chronic Obstructive Pulmonary Disease
INTERVENTIONAL
Inicio: 1 de feb de 2012
ID: NCT01555138
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
INTERVENTIONAL
Inicio: 22 de jun de 2022
ID: NCT05455684
Completado
Fase 2
ClinicalTrials.gov
Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Celivarone at 50, 100 or 300 mg OD With Amiodarone as Calibrator for the Prevention of ICD Interventions or Death
INTERVENTIONAL
Inicio: 1 de sept de 2009
ID: NCT00993382
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of IV Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Moderate to Severe Active Systemic Lupus Erythematosus While on Background Standard of Care Therapy
INTERVENTIONAL
Inicio: 14 de mar de 2024
ID: NCT05835310
Terminado
Fase 3
ClinicalTrials.gov
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
INTERVENTIONAL
Inicio: 25 de jun de 2020
ID: NCT04365868
Completado
ClinicalTrials.gov
The Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or in Combination) in Subjects With Type 2 Diabetes Previously Treated With Other Anti-diabetic Medication. A 24-week, International, Prospective, Multi-centre, Open-labelled, Non-interventional Study
OBSERVATIONAL
Inicio: 1 de nov de 2008
ID: NCT00869908
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms
INTERVENTIONAL
Inicio: 1 de sept de 2008
ID: NCT00701415
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
INTERVENTIONAL
Inicio: 21 de dic de 2023
ID: NCT06181435
Anterior
1
...
424
425
426
...
434
Siguiente
Filtros